Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease

    Access Status
    Fulltext not available
    Authors
    Yusuf, S.
    Lonn, E.
    Pais, P.
    Bosch, J.
    López-Jaramillo, P.
    Zhu, J.
    Xavier, D.
    Avezum, A.
    Leiter, L.
    Piegas, L.
    Parkhomenko, A.
    Keltai, M.
    Keltai, K.
    Sliwa, K.
    Chazova, I.
    Peters, R.
    Held, C.
    Yusoff, K.
    Lewis, B.
    Jansky, P.
    Khunti, K.
    Toff, W.
    Reid, Christopher
    Varigos, J.
    Accini, J.
    McKelvie, R.
    Pogue, J.
    Jung, H.
    Liu, L.
    Diaz, R.
    Dans, A.
    Dagenais, G.
    HOPE-3 Investigators
    Date
    2016
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Yusuf, S. and Lonn, E. and Pais, P. and Bosch, J. and López-Jaramillo, P. and Zhu, J. and Xavier, D. et al. 2016. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. The New England Journal of Medicine. 374 (21): pp. 2032-2043.
    Source Title
    N Engl J Med
    DOI
    10.1056/NEJMoa1600177
    School
    Department of Health Policy and Management
    URI
    http://hdl.handle.net/20.500.11937/45076
    Collection
    • Curtin Research Publications
    Abstract

    BACKGROUND: Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially. METHODS: In a trial with 2-by-2 factorial design, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to rosuvastatin (10 mg per day) or placebo and to candesartan (16 mg per day) plus hydrochlorothiazide (12.5 mg per day) or placebo. In the analyses reported here, we compared the 3180 participants assigned to combined therapy (with rosuvastatin and the two antihypertensive agents) with the 3168 participants assigned to dual placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included heart failure, cardiac arrest, or revascularization. The median follow-up was 5.6 years. RESULTS: The decrease in the LDL cholesterol level was 33.7 mg per deciliter (0.87 mmol per liter) greater in the combined-therapy group than in the dual-placebo group, and the decrease in systolic blood pressure was 6.2 mm Hg greater with combined therapy than with dual placebo. The first coprimary outcome occurred in 113 participants (3.6%) in the combined-therapy group and in 157 (5.0%) in the dual-placebo group (hazard ratio, 0.71; 95% confidence interval [CI], 0.56 to 0.90; P=0.005). The second coprimary outcome occurred in 136 participants (4.3%) and 187 participants (5.9%), respectively (hazard ratio, 0.72; 95% CI, 0.57 to 0.89; P=0.003). Muscle weakness and dizziness were more common in the combined-therapy group than in the dual-placebo group, but the overall rate of discontinuation of the trial regimen was similar in the two groups.CONCLUSIONS: The combination of rosuvastatin (10 mg per day), candesartan (16 mg per day), and hydrochlorothiazide (12.5 mg per day) was associated with a significantly lower rate of cardiovascular events than dual placebo among persons at intermediate risk who did not have cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; ClinicalTrials.gov number, NCT00468923.).

    Related items

    Showing items related by title, author, creator and subject.

    • Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
      Lonn, E.; Bosch, J.; López-Jaramillo, P.; Zhu, J.; Liu, L.; Pais, P.; Diaz, R.; Xavier, D.; Sliwa, K.; Dans, A.; Avezum, A.; Piegas, L.; Keltai, K.; Keltai, M.; Chazova, I.; Peters, R.; Held, C.; Yusoff, K.; Lewis, B.; Jansky, P.; Parkhomenko, A.; Khunti, K.; Toff, W.; Reid, Christopher; Varigos, J.; Leiter, L.; Molina, D.; McKelvie, R.; Pogue, J.; Wilkinson, J.; Jung, H.; Dagenais, G.; Yusuf, S.; HOPE-3 Investigators (2016)
      BACKGROUND: Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its role in persons at intermediate risk ...
    • Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
      Yusuf, S.; Bosch, J.; Dagenais, G.; Zhu, J.; Xavier, D.; Liu, L.; Pais, P.; López-Jaramillo, P.; Leiter, L.; Dans, A.; Avezum, A.; Piegas, L.; Parkhomenko, A.; Keltai, K.; Keltai, M.; Sliwa, K.; Peters, R.; Held, C.; Chazova, I.; Yusoff, K.; Lewis, B.; Jansky, P.; Khunti, K.; Toff, W.; Reid, Christopher; Varigos, J.; Sanchez-Vallejo, G.; McKelvie, R.; Pogue, J.; Jung, H.; Gao, P.; Diaz, R.; Lonn, E.; HOPE-3 Investigators (2016)
      BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated ...
    • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
      Martin, M.; Holmes, F.; Ejlertsen, B.; Delaloge, S.; Moy, B.; Iwata, H.; von Minckwitz, G.; Chia, S.; Mansi, J.; Barrios, C.; Gnant, M.; Tomaševic, Z.; Denduluri, N.; Šeparovic, R.; Gokmen, E.; Bashford, A.; Ruiz Borrego, M.; Kim, S.; Jakobsen, E.; Ciceniene, A.; Inoue, K.; Overkamp, F.; Heijns, J.; Armstrong, A.; Link, J.; Joy, A.; Bryce, R.; Wong, A.; Moran, S.; Yao, B.; Xu, F.; Auerbach, A.; Buyse, M.; Chan, Arlene; ExteNET Study Group (2017)
      Background: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.